title: Anti-beta 2-glycoprotein I antibodies of IgM class are linked to thrombotic disorders in young women without autoimmune disease.
abstract: Antiphospholipid autoantibodies particularly antibodies against beta2-glycoprotein I (anti-beta2GPI) are casually associated with thromboses in patients with autoimmune diseases. However, their exact prevalence and role in the pathogenesis of thromboses in the absence of autoimmune disease is still inconclusive. They might be particularly important when other risk factors of thrombosis are absent. We investigated antiphospholipid antibodies in 68 young women (aged <45yr at onset of the event, without autoimmune disease and with an otherwise low risk of thrombosis) in the stable period following myocardial infarction (MI), lacunar cerebral infarction (LACI) or deep vein thrombosis (DVT) and in 37 healthy age-matched controls. Patients had increased IgM anti-beta2GPI compared to controls (36.0, 11.5-49.5 vs. 17.50, 3.50-30.0 arbitrary units (AU), p<0.001), whereas no difference was obtained in other measured antibodies (anticardiolipin and antiphosphatidylserine (aPS) antibodies of IgG and IgM). IgM anti-beta2GPI positively correlated with some markers of increased coagulation potential and negatively with BMI (r=-039, p<0.005) and other parameters of the metabolic syndrome. In conclusion, we found that levels of IgM anti-beta2GPI are increased in young women suffering arterial or venous thromboses in the absence of other known autoimmune diseases and also in the absence of pronounced classical risk factors. We found that IgM anti-beta2GPI positively correlated with some markers of increased coagulation potential and negatively with parameters of the metabolic syndrome. Thus, it appears that elevated levels of IgM anti-beta2GPI are linked to thrombotic disorders in young women (without autoimmune disease) particularly when classical risk factors or the metabolic syndrome are absent.
authors.affiliation: Department of Vascular Diseases, University Medical Centre, 1000 Ljubljana, Slovenia.
authors.forename: Barbara
authors.initials: B
authors.lastname: Salobir
authors.forename: Miso
authors.initials: M
authors.lastname: Sabovic
authors.forename: Maja
authors.initials: M
authors.lastname: Hojnik
authors.forename: Sasa
authors.initials: S
authors.lastname: Cucnik
authors.forename: Tanja
authors.initials: T
authors.lastname: Kveder
mesh_terms: D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000009:adverse effects*; D000918:Antibody Specificity; D001327:Autoimmune Diseases / Q000276:immunology*; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000009:adverse effects*; D008875:Middle Aged; D012307:Risk Factors; D013927:Thrombosis / Q000276:immunology*; D053482:beta 2-Glycoprotein I / Q000276:immunology*
chemical_list: D017152:Antibodies, Antiphospholipid; D007075:Immunoglobulin M; D053482:beta 2-Glycoprotein I